The safety of allergen specific sublingual immunotherapy

Current Drug Safety

Volumn 2, Issue 2, 2007, Pages 117-123

  Passalacqua, Giovanni ^a   Guerra, Laura ^a   Compalati, Enrico ^a   Walter Canonica, Giorgio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergens; Asthma; Nasal immunotherapy; Placebo; Post marketing studies; Self administration

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; PLACEBO; RAGWEED ANTIGEN;

ABDOMINAL PAIN; AGE; ALLERGIC DISEASE; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BURNING SENSATION; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; LARYNX EDEMA; LOW DRUG DOSE; MEDICATION ERROR; META ANALYSIS; MOUTH DISEASE; NAUSEA; ORAL PRURITUS; POLLEN ALLERGY; POSTMARKETING SURVEILLANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; SINGLE DRUG DOSE; STOMACH PAIN; SUBCUTANEOUS NODULE; SWELLING; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; THROAT IRRITATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34249335685     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607780598340     Document Type: Review

References (90)

1. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; i: 1572-1573.
2. Black JH. The oral administration of pollen. J Lab Clin Med 1927; 12: 1156.
3. Herxeimer H. Bronchial hypersensitization and hyposensitization in man. Int Arch Allergy Appl Immunol 1951; 40: 40-57.
4. Taylor G, Shivalkar PR. Local nasal desensitization in allergic rhinitis. Clin Allergy 1972; 2: 125-126.
5. Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983; 38: 561-564.
6. Passalacqua G, Berardi M, Baena-Cagnani CE, Canonica GW. Oral and sublingual immunotherapy in pediatric patients. Curr Opin Allergy Immunol 2003; 3: 139-145.
7. Committee on the safety of medicines. CSM update. Desensitizing vaccines. Br Med J 1986; 293: 948.
8. Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986; 16: 483-491.
9. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987; 79: 660-677.
10. Reid MJ, Lockey RF, Turkeltaub PC, Platt-Mills TAE. Survey of fatalities from skin testing and immunotherapy. J Allergy Clin Immunol 1993; 92: 6-15.
11. Malling HJ, Weeke B. EAACI Immunotherapy position paper. Allergy 1993; 48 (suppl 44): S64.
12. Canonica GW, Passalacqua G. Non injection routes for immunotherapy. J Allergy Clin Immunol 2003; 111: 437-448.
13. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy : therapeutical vaccines for allergic diseases. World Health Organization Position Paper. Allergy 1998 : 53(Suppl 54).
14. Malling HJ. EAACI Position Paper on local immunotherapy. Allergy 1998; 53: 933-944.
15. Bousquet J, Van Cauwenberge, P. Allergic rhinits and its impact on asthma. J Allergy Clin Immunol 2001; 108(suppl 5): S146-S150.
16. Tinkelman DG, Cole WQ, Tunno J. Immunotherapy: a one-year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995; 95: 8-14.
17. Lin MS, Tanner E, Lynn J, Friday GA. Nonfatal systemic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71: 557-562
18. Ostergaard PA, Kaad PH, Kristensen T. A prospective study on the safety of immunotherapy in children with severe asthma. Allergy 1986; 41: 588-593.
19. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90: 567-578.
20. Lockey RF, Nikoara-Kasti GL, Theodoropoulos DS, Bukantz SC. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immumol 2001; 87 (1 supp): S46-S55.
21. Malling HJ. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461-472.
22. Muller U, Mosbech H. Immunotherapy with hymenoptera venom. Position Paper. Allergy 1993; 48(suppl 14): 9-35.
23. Aaronson DW, Gandhi TK. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J Allergy Clin Immunol 2004; 113: 1117-1121.
24. Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. Allergy 1986; 41: 271-279.
25. Taudorf E, Laursen CL, Lanner A, et al. Oral immunotherapy to birch pollen hay fever. J Allergy Clin Immunol 1987; 80: 153-161.
26. Mosbech H, Dreborg S, Madsenn F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one year double blind placebo controlled study. Allergy 1987; 42: 451-455.
27. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol 1990; 18: 277-284.
28. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49: 309-313.
29. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol 1995; 23: 173-178.
30. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in parietaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995; 5: 25-30.
31. Hirsch T, Sahn M, Leupold W. Double blind placebo controlled study of sublingual immunotherapy with house dust mite extracts in children. Pediatr Allergy Immunol 1997; 8: 21-27.
32. Clavel R, Bousquet J, Andre' C. Clinical efficacy of sublingual swallow immunotherapy: a double blind placebo controlled trial of a standardized five grass pollen extract in rhinitis. Allergy 1998; 53: 493-498.
33. Horak F, Stubner UE, Berger U, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract: a short term double blind study. J Invest Allergol Clin Immunol 1998; 8: 165-171.
34. Vourdas D, Syrigou E, Potamianou P, et al. Double blind placebo controlled evaluation of sublingual immunotherapy with a standardized olive tree pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive tree pollen sensitization. Allergy 1998; 53: 662-671.
35. Hordijk GJ, Antwelink JB, Luwema RA. Sublingual immunotherapy with a standardized grass pollen extract: a double blind placebo controlled study. Allergol Immunopathol 1998; 26: 234-240.
36. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite induced rhinoconjunctivitis. Lancet 1998; 351: 629-632.
37. Passalacqua G, Albano M, Riccio AM, et al. Clinical and immunological effects of a rush sublingual immunotherapy to parietaria. species: a double blind placebo controlled trial. J Allergy Clin Immunol 1999; 104: 964-968.
38. Bousquet J, Scheinmann P, Guinnepain MT, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites: a double blind placebo controlled study. Allergy 1999; 54: 249-260.
39. Pureilo D'Ambrosio, F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double blind placebo controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma or both. Allergy 1999; 54: 968-973.
40. Pradalier A, Basset D, Claudel A, et al. Sublingual swallow immunotherapy (SLIT) with a standardized five grass pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54: 819-828.
41. La Rosa M, Ranno C, Andre' C, et al. Double blind placebo controlled evaluation of sublingual swallow immunotherapy with standardized parietaria judaica extract in children with allergic rhino-conjunctivitis. J Allergy Clin Immunol 1999; 104: 425-432.
42. Guez S, Vatrinet C, Fadel R, Andre' C. House dust mite sublingual swallow immunotherapy in perennial rhinitis: a double blind placebo controlled study. Allergy 2000; 55: 369-375.
43. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunological effects of longterm sublingual immunotherapy in asthmatic children sensitized to mite: a double blind study. Allergy 2000; 55: 842-849.
44. Caffarelli C, Sensi LG, Marcucci F, Cavagni C. Preseasonal. local allergoid immnotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000; 55: 1142-1147.
45. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madr) 2001; 29: 238-244.
46. Bahceciler NN, Isik U, Barlan IB, Basaran N. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32: 49-55.
47. Voltolini S, Modena P, Minale P, et al. Sublingual immunotherapy in tree pollen allergy. Double blind, placebo controlled study with a Biologically standardized extract of tree pollen (alder, birch and hazel) administered by a rush schedule. Allergnol Immunopathol 2001: 29: 103-110.
48. Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32: 507-514.
49. Mortemousque B, Bertel F, De Casamayor J, Verin P, Colin J. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003; 33: 464-469.
50. André C, Perrin-Fayolle M, Grosclaude M, et al. A double blind placebo controlled evaluation of SLIT with a standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003; 131: 111-118.
51. Ippoliti F, De Sanctis W, Volterrani A, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14: 216-221.
52. Pajno G, Vita D, Camimiti D, Parmiani S, BArberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003; 33(12): 1641-7.
53. Wuthrich B, Bucher Ch, Jorg W, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003; 13(3): 145-8.
54. Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59(5): 491-7.
55. Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59: 498-504.
56. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114: 831-7.
57. Rolinck-Werninghaus C, Wolf H, Liebke C, et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004; 59: 1285-1293.
58. Bowen T, Greenbaum J, Charbonneau Y, et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93: 425-30.
59. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61: 185-901.
60. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: A multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006; 100(8): 1374-83.
61. Passalacqua G, Pasquali M, Ariano R, et al. Randomized double blind controlled study with sublingual carbamylated allergoid in mild rhinitis due to mites. Allergy 2006; 61(Suppl 81): 20-3.
62. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass-allergen tablets: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117(4): 802-9.
63. André C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121: 229-234.
64. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999; 54: 1110-1113.
65. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. Allergy 2001; 56: 889-892.
66. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of Sublingual immunotherapy in children with asthma. Paediatr Drugs 2003; 5: 777-81.
67. Fiocchi A, Pajno G, La Grutta S, et al. Safety of SLI T in children aged 3 TO 7 years. Ann Allergy Asthma Immunol 2005; 95(3): 254-8.
68. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing survey. Allergo Immunopathol 2004; 32: 76-81.
69. Agostinis F, Tellarini L, Falagiani P, Canonica GW, Passalacqua, G. Safety of SLIT in very young children. Allergy 2004; 60(1): 133.
70. Di Rienzo V, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005; 35: 560-4.
71. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immmunol 2006; 117(5): 1021-35.
72. Rossi R, Monasterolo RE. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Int J Immunopathol Pharmacol 2005; 18(2): 277-85.
73. Tripodi S, Di Rienzo Businco A, Benincori N, Scala G, Pingitore G. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children. Int Arch Allergy Immunol 2005; 139(2): 149-152.
74. Grosclaude M, Bouillot P, Alt R, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. Int Arch Allergy Immunol 2002; 129: 248-253.
75. Guerra L, Compalati E, Rogkakou A, Pecora S, Passalacqua G, Canonica GW. Randomized open comparison of the safety of SLIT in a no updosing and traditional updosing schedule in patients with parietaria allergy. Allergol Immunopathol 2006; 34: 82-83.
76. Rodriguez F, Boquete M, Ibanez MD, de la Torre-Martinez F, Tabar AI. Once daily sublingual immunotherapy without updosing-a new treatment schedule. Int Arch Allergy Immunol 2006; 140: 321-326.
77. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61(2): 181-4.
78. Gidaro GB, Frati F, Sensi L, Marcucci F, Incorvaia C, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35(5): 565-71.
79. Lombardi C, Canonica GW, Passalacqua G. Sublingual immunotherapy is clinically safe in patients with oral allergy syndrome. Allergy 2000; 55: 677-678.
80. Mempel M, Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: Immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003; 111: 1406-1409.
81. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the mayor Parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100: 121-129.
82. Bagnasco M, Passalacqua G, Villa G, et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31: 54-60.
83. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis (Cochrane review). Cochrane Database Syst Rev 2003; 2: CD002893.
84. Penagos M, Tarantini E, Compalati E, et al. Efficacy of sublingual immunotherapy for rhinitis. Meta analysis in pediatric patients. Ann Allergy Asthma Immunol 2006; 97(2): 141-8.
85. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long lasting effect of sublingual immunotherapy in children with asthma due to house dust mites: a ten-year prospective study. Clin Exp Allergy 2003; 33: 206-210.
86. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114: 851-7.
87. Dunsky EH, Goldstein FM, Dvorin J, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61: 1235.
88. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61: 1236.
89. Bousquet J. Sublingual immunothetapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy 2005; 60: 1-3.
90. Bieber T. Allergen-specific sublingual immunotherapy: less mystic, more scientific. Allergy 2006; 61(2): 149-50.